Related references
Note: Only part of the references are listed.Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
Takahiro Yoshizawa et al.
NPJ PRECISION ONCOLOGY (2021)
Monitoring the effectiveness of daily cleaning practices in an intensive care unit (ICU) setting using an adenosine triphosphate (ATP) bioluminescence assay
Abhishek Deshpande et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2020)
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
Valerio Gristina et al.
CANCER TREATMENT REVIEWS (2020)
A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: A case report
Xiaojie Huang et al.
LUNG CANCER (2020)
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
Byoung Chul Cho et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases
Matthew Evans et al.
PATHOLOGY & ONCOLOGY RESEARCH (2019)
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
Sheng-Kai Liang et al.
LUNG CANCER (2019)
Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples
Francesco Pepe et al.
JOURNAL OF CLINICAL PATHOLOGY (2019)
Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
Jing Huang et al.
THORACIC CANCER (2018)
EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report
Tong Zhou et al.
JOURNAL OF THORACIC DISEASE (2018)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Uncommon EGFR mutations in advanced non-small cell lung cancer
Grainne M. O'Kane et al.
LUNG CANCER (2017)
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors
Yoshitaka Seki et al.
ONCOLOGIST (2016)
Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
Yu-Ting Wang et al.
JOURNAL OF THORACIC DISEASE (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective
E. Vigliar et al.
CYTOPATHOLOGY (2015)
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma
Simona Coco et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James C-H Yang et al.
LANCET ONCOLOGY (2015)
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
Alessandro Russo et al.
ONCOTARGET (2015)
Efficiency of the Therascreen® RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas
Audrey Vallee et al.
CLINICA CHIMICA ACTA (2014)
A comparison of epidermal growth factor receptor mutation testing methods in different tissue types in non-small cell lung cancer
Suqin Yi et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2014)
Effectiveness of Gefitinib against Non-Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
Satoshi Watanabe et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Novel EGFR Mutation in Exon 19 Showed Stable Disease After TKI Treatment
Anthonie J. van der Wekken et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations
Tommaso De Pas et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
Jenn-Yu Wu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
S-G. Wu et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
A. G. Pallis et al.
BRITISH JOURNAL OF CANCER (2007)
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature
Dongqing Gu et al.
HUMAN MUTATION (2007)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors
L. V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mutations of the epidermal growth factor receptor in non-small cell lung cancer - Search and destroy
SK Chan et al.
EUROPEAN JOURNAL OF CANCER (2006)
The relationship between epidermal growth factor receptor (EGFR) mutations and clinicopathologic features in non-small cell lung cancers
M Tukumo et al.
LUNG CANCER (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Share Paper
